"Preclinical Data Supportive of Ongoing Clinical Collaboration Trials Evaluating FAK Inhibition in Combination with Chemotherapeutic and Immunotherapeutic Agents"
IMO this is the real reason for the previous run-up: Defactinib -- a FAK Inhibitor -- which in my opinion is going to be the real driver moving forward. Don't get me wrong DUO data is important as a driver for near-term revenue. But, Defactinib is the "biggee" as in being a game changer for treating 2 very stubborn cancers: Pancreatic and Breast cancer.
I don't think people realize or appreciate the HUGE news we just got 😁😁😎😎🤑🤑
KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float O/S 10.6 M / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys
Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.
KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously
Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial
Marketing potential Pipeline candidates address large, multi-billion dollar markets
Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.
Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.
Mid year (june thru july) is almost done right? I saw many articles that said the news would be in june 2017.
whats the deal?
Hiring an experienced CFO with audit experience indicates a high level of confidence that duvelisib will be generating significant revenue, especially since the company already has a financial person.
MicroCap Alert to VSTM shareholders. Why Clean Energy Technologies (CETY) shares moved up recently and why they are about to rise sharply again. CETY purchased their Heat Recovery Systems from General Electric. Each system sells for about $300,000. Demand for CETY HRS is very strong. CETY just expanded Europe sales and service office in high demand market CETY immediately announced first new sale in Europe CETY presenting to 26 Power Companies in the Pacific on July 31st to August 4th – These 26 power companies need CETY HRS to produce power cheaper and make more profits.
Expect substantial sales orders to flow soon after conference CETY 1017 target: $.15 to $.20
Penny, Nickle, Maybe a Dime ??? Oh Yeah We Had To Give New CFO 300,000 Shares. Look Out She's From The Clinton Foundation. This Stock Maybe Worthless By The End Of The Year, If The Clinton Name Is Anywhere In A Portfolio.???
I bought at $1.25 All The Way To The Bank!!!! Hold On Baby It's Long And Hard.
Yes...let's squeeze all of these pesky shorts out so that we can have some stability. The price is climbing back up nicely.....
Verastem (VSTM) which has made a huge move recently is finally getting some positive acknowledgement in the analyst community. After having Hold ratings reiterated at Jefferies and Cantor Fitzgerald over the past month, Oppenheimer today takes a more optimistic view on the company with a Buy rating and $6 price target. Positive trial results have really bolstered the shares so far in July and the company named a new CFO this week as well. The shares have also now doubled since we did a Spotlight feature on this small concern in June.
Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
Guess the fundamental level is about 4. The run to 4.54 was the shorts getting squeezed, painfully. This is a tough one to short. With volume 10x a month or two ago it is no longer day traders calling the shots. It's bigger players with good sources of info. Low valuation with a potential Phase 3 to read out probably in August. Also big players (Merck and Pfizer) probably watching the Ph 1 combo trials with defactinib.
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.1 In other words, the correlation coefficient of the other stock
can anyone please give give me a prediction. whether it be for short term hold or long term?
Going to 4 today feeling
Excellent job short boys! Get ready for some more massive losses...
close in the green today?
Good luck with 5's this week haha... start of a multi day rundown here with nothing getting released... short all the way back to reality for me here.